verified SJR 0,691 · Q2 • database Scopus / SJR & Web of Science & DOAJ indexed

United Kingdom · Adis International Ltd

workspace_premium Q2 — Pharmacology visibility_off Single blind Peer Review lock_open Open Access · DOAJ

Drugs in R and D

Drugs in R and D is a journal indexed in SJR in Pharmacology with an H index of 56. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 2700 €. The scope of the journal is focused on pharmacology, drug development, drug research. It has an SJR impact factor of 0,691 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,691.

ISSN: 1174-5886

Publisher: Adis International Ltd

Category: Pharmacology

Indexation: verifiedScopus / SJR verifiedWeb of Science verifiedDOAJ

open_in_new Portal NPD menu_book Author guidelines

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,691 Q2

H-index 56

Acceptance rate pie_chart

31%

Source Acceptance_Rate

Time to publication hourglass_top

14 weeks

Field Average_time_publication_weeks

Publication cost (APC) payments

2.700 € Open Access

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science DOAJ

SJR Impact

0,691

H-index

Docs (year)

Docs 3y

111

Total refs

1772

Cites 3y

264

Citable 3y

108

Cites/Doc 2y

2.23

Ref/Doc

35.44

Immediate OA

2700 €

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Beclometasone Oral ??? DOR BioPharma

Zatosetron

Decitabine

Current Efforts on Generation of Optimal Immune Responses against HIV through Mucosal Immunisations

Correction to: Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication

CJ 11974

Cinacalcet Does Not Affect the??Pharmacokinetics or Pharmacodynamics of Warfarin

Cethromycin

CDP 571

BTS 67582

Botulinum Toxin for Pain

Blonanserin

SHOW MORE ARTICLES

Benzimidavir

A Chaperone-Mediated Approach to??Enzyme Enhancement as a Therapeutic Option for the Lysosomal??Storage Disorders

Assessment of the Prophylactic Role of Aspirin and/or Clopidogrel on Experimentally Induced Acute Myocardial Infarction in Hypercholesterolemic Rats

Aripiprazole

Antiemetics for Cancer Chemotherapy-Induced Nausea and Vomiting

Antibacterial Effects of Moxifloxacin and Levofloxacin Simulating Epithelial Lining Fluid Concentrations against Community-Acquired Methicillin-Resistant Staphylococcus aureus

Anidulafungin

Alvimopan

Aldesleukin

Agents in Development for the Treatment of Hepatitis C

Acknowledgement

FAQs

Drugs in R and D has an SJR of 0,691 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is 2700 EUR.

The acceptance rate recorded for Drugs in R and D is 31%.

Drugs in R and D

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Drugs in R and D?

What is the APC / publication cost?

What is the acceptance rate?